A systems approach to clinical oncology: Focus on breast cancer
Author Information
Author(s): Mark Abramovitz, Brian Leyland-Jones
Primary Institution: McGill University
Hypothesis
Genomic and proteomic platforms can improve the classification and treatment of breast cancer.
Conclusion
The study emphasizes the need for a combined genomic and proteomic approach to enhance breast cancer diagnosis and treatment.
Supporting Evidence
- Genomic microarrays have improved the classification of breast tumors.
- FFPE tumor samples are a critical resource for clinical research.
- The Oncotype DX assay has been validated for predicting recurrence in breast cancer patients.
Takeaway
This study looks at how scientists can use new technologies to better understand and treat breast cancer by looking at genes and proteins.
Methodology
The review discusses various genomic and proteomic technologies applied to breast cancer research, including microarrays, qRT-PCR, and tissue microarrays.
Limitations
The reliance on frozen tumor samples limits the ability to conduct large-scale validation studies.
Participant Demographics
The study includes breast cancer patients, with a focus on those with invasive breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website